Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

USA - NASDAQ:GPCR - US86366E1064 - ADR

32.22 USD
+2.65 (+8.96%)
Last: 10/30/2025, 8:13:51 PM
32.25 USD
+0.03 (+0.09%)
After Hours: 10/30/2025, 8:13:51 PM
Fundamental Rating

3

Overall GPCR gets a fundamental rating of 3 out of 10. We evaluated GPCR against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for GPCR as it has an excellent financial health rating, but there are worries on the profitability. GPCR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GPCR has reported negative net income.
GPCR had a negative operating cash flow in the past year.
In the past 5 years GPCR always reported negative net income.
In the past 5 years GPCR always reported negative operating cash flow.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

GPCR has a Return On Assets (-21.92%) which is in line with its industry peers.
With a decent Return On Equity value of -23.18%, GPCR is doing good in the industry, outperforming 65.10% of the companies in the same industry.
Industry RankSector Rank
ROA -21.92%
ROE -23.18%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, GPCR has more shares outstanding
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

An Altman-Z score of 22.51 indicates that GPCR is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 22.51, GPCR belongs to the best of the industry, outperforming 91.67% of the companies in the same industry.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.51
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 20.48 indicates that GPCR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 20.48, GPCR belongs to the top of the industry, outperforming 91.15% of the companies in the same industry.
GPCR has a Quick Ratio of 20.48. This indicates that GPCR is financially healthy and has no problem in meeting its short term obligations.
GPCR has a Quick ratio of 20.48. This is amongst the best in the industry. GPCR outperforms 91.15% of its industry peers.
Industry RankSector Rank
Current Ratio 20.48
Quick Ratio 20.48
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

GPCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.21%.
EPS 1Y (TTM)-58.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GPCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.37% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.48%
EPS Next 2Y6.93%
EPS Next 3Y3.5%
EPS Next 5Y11.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GPCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.93%
EPS Next 3Y3.5%

More info and screens

0

5. Dividend

5.1 Amount

GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (10/30/2025, 8:13:51 PM)

After market: 32.25 +0.03 (+0.09%)

32.22

+2.65 (+8.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners95.19%
Inst Owner Change-0.07%
Ins Owners3.04%
Ins Owner Change5.22%
Market Cap1.86B
Revenue(TTM)N/A
Net Income(TTM)-178950000
Analysts86.67
Price Target77.36 (140.1%)
Short Float %26.72%
Short Ratio4.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-265.43%
Min EPS beat(2)-283.91%
Max EPS beat(2)-246.94%
EPS beat(4)0
Avg EPS beat(4)-237.39%
Min EPS beat(4)-283.91%
Max EPS beat(4)-202.27%
EPS beat(8)1
Avg EPS beat(8)-173.88%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.09%
PT rev (3m)-4.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-22.71%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)-28.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.4
P/tB 2.4
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0
BVpS13.4
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.92%
ROE -23.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.48
Quick Ratio 20.48
Altman-Z 22.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y31.48%
EPS Next 2Y6.93%
EPS Next 3Y3.5%
EPS Next 5Y11.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-77.3%
EBIT Next 3Y-32.9%
EBIT Next 5Y-5.94%
FCF growth 1Y-44.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.73%
OCF growth 3YN/A
OCF growth 5YN/A

STRUCTURE THERAPEUTICS INC / GPCR FAQ

What is the ChartMill fundamental rating of STRUCTURE THERAPEUTICS INC (GPCR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to GPCR.


Can you provide the valuation status for STRUCTURE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to STRUCTURE THERAPEUTICS INC (GPCR). This can be considered as Overvalued.


How profitable is STRUCTURE THERAPEUTICS INC (GPCR) stock?

STRUCTURE THERAPEUTICS INC (GPCR) has a profitability rating of 1 / 10.


What is the earnings growth outlook for STRUCTURE THERAPEUTICS INC?

The Earnings per Share (EPS) of STRUCTURE THERAPEUTICS INC (GPCR) is expected to grow by 31.48% in the next year.